Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2015 1
2016 2
2018 1
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Current and future direction in the management of scleroderma.
Brady SM, Shapiro L, Mousa SA. Brady SM, et al. Arch Dermatol Res. 2016 Sep;308(7):461-71. doi: 10.1007/s00403-016-1647-6. Epub 2016 Apr 30. Arch Dermatol Res. 2016. PMID: 27139430 Review.
Scleroderma is a heterogeneous disease with a complex etiology. As more information is gained about the underlying mechanisms and the improved classifications of scleroderma subtypes, treatments can be better personalized. ...Two recently FDA-approved antifib
Scleroderma is a heterogeneous disease with a complex etiology. As more information is gained about the underlying mechanisms
Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons.
Jee AS, Sahhar J, Youssef P, Bleasel J, Adelstein S, Nguyen M, Corte TJ. Jee AS, et al. Pharmacol Ther. 2019 Oct;202:40-52. doi: 10.1016/j.pharmthera.2019.05.014. Epub 2019 May 31. Pharmacol Ther. 2019. PMID: 31153954 Review.
Disease behaviour in interstitial lung disease (ILD) is highly variable and accurate clinical tools to predict prognosis and guide management decisions remain unsatisfactorily elusive. ...The aim is to review the rationale, potential and limitations of cur
Disease behaviour in interstitial lung disease (ILD) is highly variable and accurate clinical tools to predict prognosis and g
The contemporary management of systemic sclerosis.
Eldoma M, Pope J. Eldoma M, et al. Expert Rev Clin Immunol. 2018 Jul;14(7):573-582. doi: 10.1080/1744666X.2018.1485490. Epub 2018 Jun 20. Expert Rev Clin Immunol. 2018. PMID: 29874475 Review.
We will outline an approach to treatment of SSc based on disease manifestations and current evidence. Expert commentary: This complex disease is currently treated with therapies developed for similar indications such as for vascular manifestations of S …
We will outline an approach to treatment of SSc based on disease manifestations and current evidence. Expert commentary: This …
Current approaches to the management of early active diffuse scleroderma skin disease.
Nihtyanova SI, Denton CP. Nihtyanova SI, et al. Rheum Dis Clin North Am. 2008 Feb;34(1):161-79; viii. doi: 10.1016/j.rdc.2007.11.005. Rheum Dis Clin North Am. 2008. PMID: 18329538 Review.
In the diffuse cutaneous subset, skin involvement is often extensive and warrants direct therapy. Currently, broad spectrum immunosuppressive strategies are used, but more targeted specific approaches are now emerging. This article reviews the evidence for efficacy …
In the diffuse cutaneous subset, skin involvement is often extensive and warrants direct therapy. Currently, broad spectrum im …
From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis.
Del Papa N, Zaccara E. Del Papa N, et al. Best Pract Res Clin Rheumatol. 2015 Dec;29(6):756-69. doi: 10.1016/j.berh.2016.02.004. Epub 2016 Mar 30. Best Pract Res Clin Rheumatol. 2015. PMID: 27107511 Review.
Despite significant progress over the past decades, the clinical management of patients with SSc remains a challenge. Novel therapies are currently being tested in the treatment of SSc and have the potential for modifying the disease process and improving the …
Despite significant progress over the past decades, the clinical management of patients with SSc remains a challenge. Novel therapies …
Diagnosis and Management of Systemic Sclerosis: A Practical Approach.
Lee JJ, Pope JE. Lee JJ, et al. Drugs. 2016 Feb;76(2):203-13. doi: 10.1007/s40265-015-0491-x. Drugs. 2016. PMID: 26659258 Review.
Still, significant disease modifying therapies do not yet exist for most patients. Therefore, organ-based management strategies are employed and research has been directed within this paradigm focusing on either the most debilitating symptoms, such as Raynaud …
Still, significant disease modifying therapies do not yet exist for most patients. Therefore, organ-based management strategie …